Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01486888
First received: December 5, 2011
Last updated: NA
Last verified: December 2011
History: No changes posted

December 5, 2011
December 5, 2011
May 2006
July 2006   (final data collection date for primary outcome measure)
  • Area under the serum insulin concentration-time curve (AUC 0-24 hours) [ Designated as safety issue: No ]
  • Maximum serum insulin concentration (Cmax) [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Area under the serum insulin concentration-time curve (AUC 0-6 hours) [ Designated as safety issue: No ]
  • Area under the serum insulin concentration-time curve (AUC 6-24 hours) [ Designated as safety issue: No ]
  • Area under the serum insulin concentration-time curve (AUC 0-inifinity hours) [ Designated as safety issue: No ]
  • Time to maximum serum insulin concentration (tmax) [ Designated as safety issue: No ]
  • Terminal insulin half life (t½) [ Designated as safety issue: No ]
  • Adverse events [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects
A Randomised, Single Centre, Double-blind, Two-period Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Insulin Mixtard® 30 (600 Nmol/ml) and Insulin Mixtard® 30 (1998 Nmol/ml) in Healthy Subjects

This trial is conducted in Europe. The aim of this trial is to to test for bioequivalence between two formulations of Mixtard® 30 in healthy subjects.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Diabetes
  • Healthy
Drug: biphasic human insulin 30
Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
  • Experimental: Formulation A
    Intervention: Drug: biphasic human insulin 30
  • Active Comparator: Formulation B
    Intervention: Drug: biphasic human insulin 30
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
July 2006
July 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator
  • Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2, inclusive
  • Non-smoker, defined as no nicotine consumption for at least one year
  • Fasting plasma glucose below or equal to 100 mg/dL (5.6 mmol/L)

Exclusion Criteria:

  • Previous participation in this trial or other clinical trials within the last 3 months
  • Body weight above 87.5 kg
  • Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (intrauterine device (IUD) that has been in place for at least 3
  • History of alcohol or drug abuse
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01486888
EX1000-1735, 2005-006050-24
No
Public Access to Clinical Trials, Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Jan Lynge Novo Nordisk A/S
Novo Nordisk A/S
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP